Guide to Submitting Written Testimony to the FDA about NurOwn

The FDA invites people to submit written comments about NurOwn to the AdComm panel for their review prior to the September 27th meeting.

August 3, 2023

FOR PRESS INQUIRIES

[email protected]

See our coverage on

UPDATE: I AM ALS delivers petition signed by 30,000 to FDA’s Dr. Peter Marks

Today, we delivered a petition of over 30,000 signatories to Dr. Peter Marks at the FDA!

Co-Founder Brian Wallach pens letter to CEO of Cigna about Relyvrio

I am outraged by Cigna’s inhumane decision to discontinue coverage to Relyvrio for people with ALS.

Guide to Submitting Written Testimony to the FDA about Tofersen

On September 7, 2022, the FDA will host their second public advisory committee meeting (AdCom) about AMX0035.

Our Approach on Synapticure

A Look Back at 2022

We are a community-centric platform and we value transparency and a commitment to our mission to end ALS. We stand ready to be accountable for our commitments, when we excel and when we fall short. Here are the commitments we made in 2021 and where we stand one year later.

I AM ALS comments regarding FDA refusal to file

Yesterday, the Food and Drug Administration (FDA) issued a refusal to file letter regarding NurOwn.

We will find cures for ALS. The only question is when. That answer depends on you.

Stay informed on I AM ALS’ progress and what you can do to help us make hope real.

I AM ALS supports PVA comments to FAA regarding air accessibility and safety for people with disabilities

NINDS releases draft of ALS Strategic Plan

I AM ALS is pleased that the National Institute of Neurological Disorders and Stroke (NINDS) released their ALS Strategic Plan.

NINDS has awarded the first Expanded Access Grant under ACT for ALS

Today, September 30, 2022, the National Institute of Neurological Disorders and Stroke (NINDS) awarded the first of what we hope to be many Expanded Access Program (EAP) grants to help people with Amyotrophic Lateral Sclerosis (ALS) who do not qualify for clinical trials.

I AM ALS statement regarding 7 – 2 vote in favor of AMX0035 approval

On September 7, 2022, the Peripheral and Central Nervous System Drugs Advisory Committee (AdCom) met for the second time to discuss the New Drug Application (NDA) for AMX0035. After hearing from clinicians, scientists, field experts, and people living with ALS, the committee voted 7 - 2 in favor of approval!

Comments from ALS Organizations United in Support of AMX0035 Approval

Guide to Submitting Written Testimony to the FDA about AMX0035